Fennec Pharmaceuticals (TSE:FRX) Sets New 52-Week Low at $8.41

Fennec Pharmaceuticals Inc. (TSE:FRX)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$8.41 and last traded at C$8.41, with a volume of 204 shares trading hands. The stock had previously closed at C$8.49.

Fennec Pharmaceuticals Trading Down 2.9 %

The stock’s 50 day simple moving average is C$10.69 and its 200 day simple moving average is C$12.67. The firm has a market cap of C$225.12 million, a PE ratio of 169.80 and a beta of 0.46. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 6.93.

Fennec Pharmaceuticals (TSE:FRX) last announced its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported C$0.56 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.67 by C($0.11). Fennec Pharmaceuticals had a net margin of 6.33% and a negative return on equity of 1,005.59%. The business had revenue of C$34.21 million during the quarter, compared to analysts’ expectations of C$14.19 million. On average, sell-side analysts forecast that Fennec Pharmaceuticals Inc. will post 1.1958225 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Senior Officer Adrian J. Haigh acquired 22,222 shares of the stock in a transaction on Monday, April 15th. The stock was acquired at an average cost of C$2.31 per share, for a total transaction of C$51,332.82. 17.27% of the stock is owned by insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.